Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
The University of Texas MD Anderson Cancer Center · NRG Oncology · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
601
total citations
- FWCI
- 68.90
- Percentile
- 100%
- References
- 34
Citations per year
Authors
19- RLRobert L. ColemanCorresponding
The University of Texas MD Anderson Cancer Center
- MFMark F. Brady
NRG Oncology, University at Buffalo, State University of New York, Gynecologic Oncology Group
- TJThomas J. Herzog
University of Cincinnati
- PSPaul Sabbatini
Memorial Sloan Kettering Cancer Center
- DKDeborah K. Armstrong
Sidney Kimmel Cancer Center
Topics & keywords
Topics
Keywords
- Medicine
- Gynecologic oncology
- Carboplatin
- Bevacizumab
- Paclitaxel
- Ovarian cancer
- Oncology
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.